![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/9/94/Coronavirus._SARS-CoV-2.png/640px-Coronavirus._SARS-CoV-2.png&w=640&q=50)
Sanofi–GSK COVID-19 vaccine
Vaccine candidate against COVID-19 / From Wikipedia, the free encyclopedia
The Sanofi–GSK COVID-19 vaccine sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.[3][4]
Quick Facts Vaccine description, Target ...
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Trade names | Vidprevtyn Beta |
Other names | VAT00002, VAT00008 |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
Close
The Sanofi–GSK COVID‑19 vaccine was approved for medical use in the European Union in November 2022.[1][2][5][6]